The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10651 malaria professionals are enjoying the free benefits of MalariaWorld today

infants

Profiles of Plasmodium falciparum infections detected by microscopy through the first year of life in Kintampo a high transmission area of Ghana

October 21, 2020 - 08:36 -- Open Access
Author(s): 
Botwe AK, Owusu-Agyei S, Asghar M, Hammar U, Oppong FB, Gyaase S, Dosoo D, Jakpa G, Boamah E, Twumasi MF, Osier F, Färnert A, Asante KP
Reference: 
PLoS One. 2020 Oct 19;15(10):e0240814

Although malaria mortality among children under five years of age is high, the characteristics of their infection patterns are not well described. The aim of this study was to examine the longitudinal sequence pattern of Plasmodium falciparum infections in the first year of life within a birth cohort in Kintampo, Ghana (N = 1855). Infants were monitored at home with monthly sampling and also at the clinic for any febrile illness between 2008 and 2011.

NOT Open Access | Feasibility of direct venous inoculation of the radiation-attenuated Plasmodium falciparum whole sporozoite vaccine in children and infants in Siaya, western Kenya

May 25, 2020 - 08:00 -- NOT Open Access
Author(s): 
Oneko M, Cherop YR, Steinhardt LC, et al.
Reference: 
Vaccine. 2020 May 19:S0264-410 X (20)30614-9

PfSPZ Vaccine, composed of radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria. A critical issue for advancing vaccines that are administered intravenously is the ability to efficiently administer them across multiple age groups. As part of a pediatric safety, immunogenicity, and efficacy trial in western Kenya, we evaluated the feasibility and tolerability of DVI, including ease of venous access, injection time, and crying during the procedure across age groups.

Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa

January 24, 2020 - 14:40 -- Open Access
Author(s): 
Otieno L, Guerra Mendoza Y, Oneko M, et al.
Reference: 
Vaccine Volume 38, Issue 4, 22 January 2020, Pages 897-906

We assessed the safety and immunogenicity of the RTS,S/AS01 malaria vaccine in a subset of children identified as HIV-infected during a large phase III randomized controlled trial conducted in seven sub-Saharan African countries.

Pharmacokinetic Predictors for Recurrent Malaria After Dihydroartemisinin-Piperaquine Treatment of Uncomplicated Malaria in Ugandan Infants

May 8, 2013 - 19:24 -- Open Access
Author(s): 
Darren J. Creek, Victor Bigira, Shelley McCormack, Emmanuel Arinaitwe, Humphrey Wanzira, Abel Kakuru, Jordan W. Tappero, Taylor G. Sandison, Niklas Lindegardh, Francois Nosten, Francesca T. Aweeka and Sunil Parikh
Reference: 
J Infect Dis. (2013) 207 (11): 1646-1654.
MalariaWorld

We conducted a prospective PK/PD study of piperaquine in 107 young children in Uganda. Samples were collected up to 28 days after 218 episodes of malaria treatment, which occurred during follow-up periods of up to 5 months. 

Country: 
Subscribe to RSS - infants